

RESEARCH ARTICLE

Hypoalbuminemia is a frequent marker of increased mortality in cardiogenic shock

Toni Jäntti^{1*}, Tuukka Tarvasmäki¹, Veli-Pekka Harjola², John Parissis³, Kari Pulkki⁴, Tuija Javanainen¹, Heli Tolppanen¹, Raija Jurkko¹, Mari Hongisto², Anu Kataja², Alessandro Sionis⁵, Jose Silva-Cardoso⁶, Marek Banaszewski⁷, Jindrich Spinar⁸, Alexandre Mebazaa⁹, Johan Lassus¹, for the CardShock investigators[¶]

1 Cardiology, University of Helsinki and Department of Cardiology, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland, **2** Emergency Medicine, University of Helsinki and Department of Emergency Medicine and Services, Helsinki University Hospital, Helsinki, Finland, **3** Heart Failure Clinic and Secondary Cardiology Department, Attikon University Hospital, Athens, Greece, **4** Laboratory Division, Turku University Hospital and Department of Clinical Chemistry, University of Turku, Turku, Finland, **5** Intensive Cardiac Care Unit, Cardiology Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute IIB-Sant Pau, Universidad Autónoma de Barcelona, Barcelona, Spain, **6** Department of Cardiology, CINTESIS, Porto Medical School, São João Hospital Center, University of Porto, Porto, Portugal, **7** Intensive Cardiac Therapy Clinic, Institute of Cardiology, Warsaw, Poland, **8** Department of Internal Medicine and Cardiology, University Hospital Brno, Brno, Czech Republic, **9** INSERM U942, University Paris Diderot and Department of Anesthesia and Critical Care, Hôpital Lariboisière, APHP, Paris, France

[¶] The list CardShock investigators is provided in the Acknowledgments

* toni.jantti@finnet.fi


 OPEN ACCESS

Citation: Jäntti T, Tarvasmäki T, Harjola V-P, Parissis J, Pulkki K, Javanainen T, et al. (2019) Hypoalbuminemia is a frequent marker of increased mortality in cardiogenic shock. *PLoS ONE* 14(5): e0217006. <https://doi.org/10.1371/journal.pone.0217006>

Editor: Corstiaan den Uil, Erasmus Medical Center, NETHERLANDS

Received: March 6, 2019

Accepted: May 2, 2019

Published: May 16, 2019

Copyright: © 2019 Jäntti et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files.

Funding: VPH was supported by the Aarne Koskelo Foundation (no grant number): <http://www.aarnekoskelonsaatio.fi/>, and the Finnish Cardiac Foundation (no grant number): <https://www.fincardio.fi/>. Laboratory kits were provided by Roche Diagnostics. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Abstract

Introduction

The prevalence of hypoalbuminemia, early changes of plasma albumin (P-Alb) levels, and their effects on mortality in cardiogenic shock are unknown.

Materials and methods

P-Alb was measured from serial blood samples in 178 patients from a prospective multinational study on cardiogenic shock. The association of hypoalbuminemia with clinical characteristics and course of hospital stay including treatment and procedures was assessed. The primary outcome was all-cause 90-day mortality.

Results

Hypoalbuminemia (P-Alb < 34g/L) was very frequent (75%) at baseline in patients with cardiogenic shock. Patients with hypoalbuminemia had higher mortality than patients with normal albumin levels (48% vs. 23%, $p = 0.004$). Odds ratio for death at 90 days was 2.4 [95% CI 1.5–4.1] per 10 g/L decrease in baseline P-Alb. The association with increased mortality remained independent in regression models adjusted for clinical risk scores developed for cardiogenic shock (CardShock score adjusted odds ratio 2.0 [95% CI 1.1–3.8], IABP-SHOCK II score adjusted odds ratio 2.5 [95%CI 1.2–5.0]) and variables associated with hypoalbuminemia at baseline (adjusted odds ratio 2.9 [95%CI 1.2–7.1]). In serial measurements, albumin levels decreased at a similar rate between 0h and 72h in both survivors and

Competing interests: VPH: Advisory board fees from Roche Diagnostics, research grant from Abbott, speaker fees from Orion, all outside the present work. KP: Advisory board fees from Roche Diagnostics (Finland). AM: lecture fees from Novartis, Orion, and Abbott, research grants from Roche, and consultant fees from Servier and Sanofi, all outside the present work. JL: Speakers bureau and consultancy fees: AstraZeneca, Bayer, Boehringer-Ingelheim, Novartis, OrionPharma, Pfizer, Roche Diagnostics, and ViforPharma, all outside the present work. All other authors report that they have no competing interests. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

nonsurvivors (Δ P-Alb -4.6 g/L vs. 5.4 g/L, $p = 0.5$). While the decrease was higher for patients with normal P-Alb at baseline ($p < 0.001$ compared to patients with hypoalbuminemia at baseline), the rate of albumin decrease was not associated with outcome.

Conclusions

Hypoalbuminemia was a frequent finding early in cardiogenic shock, and P-Alb levels decreased during hospital stay. Low P-Alb at baseline was associated with mortality independently of other previously described risk factors. Thus, plasma albumin measurement should be part of the initial evaluation in patients with cardiogenic shock.

Trial registration

[NCT01374867](https://clinicaltrials.gov/ct2/show/study/NCT01374867) at ClinicalTrials.gov.

Introduction

Hypoalbuminemia is a frequent finding both in chronic illness[1] and acute conditions[2]. In chronic illness hypoalbuminemia has been attributed to decreased albumin synthesis due to wasting and cachexia[3,4], although recent literature suggests that increased catabolism is more often the cause[5]. In acute conditions the mechanisms contributing to hypoalbuminemia differ from chronic disease as the major cause of hypoalbuminemia in the acute setting is capillary leakage into the interstitial space due to inflammatory processes[6]. In addition, decreased synthesis, haemodilution due to fluid administration, renal and gut losses due to congestion, and increased catabolism also play a role[5,7,8].

The association of hypoalbuminemia with increased mortality has been described in detail for end-stage renal disease[9] but it has also been established in varied conditions such as trauma[10], critical illness[7], cancer[11], chronic heart failure[12,13] as well as in the elderly [14]. More recently, the role of albumin has attracted attention also in acute cardiac conditions. Hypoalbuminemia has been shown to be associated with an increase in the rate of complications[15,16] and long-term mortality[16] in acute myocardial infarction, as well as worse outcomes in acute heart failure[17–19].

Cardiogenic shock is the most severe form of acute heart failure characterized by a low cardiac output resulting in low blood pressure and hypoperfusion[20]. The most common cause of cardiogenic shock is acute myocardial infarction[21]. Inflammatory and neurohormonal responses play a central role in the pathophysiology of cardiogenic shock[22], but the prevalence of hypoalbuminemia and its effect on mortality remains unexplored.

The purpose of this study was to investigate the prevalence and prognostic significance of plasma albumin (P-Alb) in patients with cardiogenic shock. Furthermore, we explored factors associated with hypoalbuminemia and changes in albumin levels during hospitalization.

Materials and methods

The CardShock study (NCT01374867 at www.clinicaltrials.gov) is a European prospective, observational, multicentre and multinational study on cardiogenic shock. Recruitment was conducted between October 2010 and 31 December 2012. The study enrolled patients from emergency departments, cardiac and intensive care units, as well as catheter laboratories in nine tertiary hospitals from eight countries. The study was approved by the following ethics

committees: Athens: Ethics Committee of Attikon University Hospital; Barcelona: Health Research Ethics Committee of the Hospital de Sant Pau; Brescia: Ethics Committee of the Province of Brescia; Brno: Ethic committee of University Hospital Brno; Helsinki: The Ethics Committee, Department of Medicine, The Hospital District of Helsinki and Uusimaa; Porto: Ethics committee of S. João Hospital Center/Porto Medical School; Rome: Ethical Committee Sant'Andrea Hospital; Warsaw: Local Bioethics Committee of the Institute of Cardiology. Copenhagen: The study was approved by the Danish Protection Agency with reference number GEH-2014-013; I-Suite number: 02731. The study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from the patient or next of kin if the patients were unable to give the consent on admission.

Inclusion criteria and data collection

Consecutive patients aged over 18 years were enrolled in the study within 6 hours from identification of cardiogenic shock. The inclusion criteria were (1) an acute cardiac cause for the shock, and (2) systolic blood pressure <90mmHg (after adequate fluid challenge) for 30min or a need for vasopressor therapy to maintain systolic blood pressure >90mmHg, and (3) signs of hypoperfusion (any of the following: altered mental status, cold periphery, oliguria <0.5mL/kg/h for the previous 6 h, or blood lactate >2 mmol/L) (for details see Harjola et al.[21]). Exclusion criteria were shock caused by ongoing hemodynamically significant arrhythmia or shock after cardiac or non-cardiac surgery. The etiology of cardiogenic shock was determined by local investigators. Acute coronary syndrome etiology was defined as shock caused by myocardial infarction (with or without ST-elevation). Echocardiography was performed per protocol at study entry. Patients were treated according to local practice, and treatment and procedures were registered.

The study cohort consists of 178 patients with plasma samples available at baseline. Blood was drawn within 3 hours of study enrollment. Additionally, serial blood samples were collected at 12 h, 24 h, 36 h, 48 h and 72h (all +/-3 h). Separated plasma was immediately frozen in aliquots and stored at -80°C. Creatinine, C-reactive protein (CRP), high-sensitivity troponin T (hsTnT), N-terminal pro b-type natriuretic peptide (NT-proBNP), alanine aminotransferase, alkaline phosphatase, total bilirubin, and albumin (P-Alb) (Roche Diagnostics, Basel, Switzerland) were analyzed from the plasma samples at a central accredited laboratory (ISLAB, Kuopio, Finland). The reference limit used for hypoalbuminemia was <34 g/L as recommended by the central laboratory, and has also been used in several studies on heart failure [12,13,18,23]. Arterial blood lactate and haemoglobin were analysed locally. Estimated glomerular filtration rate (eGFR) was calculated from creatinine values using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation[24]. Central venous pressure was recorded at 72 hours in 65 patients with a central venous line.

The primary endpoint was all-cause 90-day mortality. Vital status during follow-up was determined through direct contact with the patient or next of kin, or through population and hospital registers. Two patients were lost to follow-up. The study was approved by local ethics committees and conducted in accordance with the Declaration of Helsinki.

Statistical analysis

Results are presented as numbers (n) and percentages (%), means and standard deviations (SD) for normally distributed variables, or median and interquartile range (IQR) for variables with a skewed distribution. Categorical variables were compared using Chi-squared or Fisher's exact test whereas Mantel-Haenszel trend test was used for ordinal variables. Between-group comparisons were performed using two-way analysis of variance, Student's t-test or Mann-

Whitney U-test, as appropriate. Associations between continuous variables were assessed using Pearson and Spearman correlations for normally and non-normally distributed variables, respectively. Differences in survival between groups were assessed by Kaplan–Meier survival curves and log-rank test. The significance of changes in albumin levels between different time points was tested using a paired-samples T-test. Logistic regression analysis was used to identify variables associated with baseline hypoalbuminemia. To determine baseline variables independently associated with hypoalbuminemia, variables with a univariable $p < 0.10$ were entered into a multivariable logistic regression model. For the selection of independently associated variables, both forward and backward conditional and likelihood ratio models were used. Receiver operating characteristics analysis was used to select the multivariable model with the highest area under the curve for predicting baseline hypoalbuminemia. Multivariable logistic regression models were used to test for the independent association between plasma albumin and 90-day mortality. Multivariable adjustments were made for 1) variables statistically significantly associated with hypoalbuminemia at baseline ($p < 0.05$), i.e. smoking status, comorbidities (heart failure with reduced ejection fraction, coronary artery disease, prior myocardial infarction), calcium-channel blocker use, lung oedema on X-ray, BMI, eGFR, haemoglobin, NT-proBNP, and CRP at baseline, and presence of multi-vessel disease in primary coronary angiography, as well as 2) contemporary risk prediction models in cardiogenic shock such as the CardShock risk score[21], the IABP-SHOCK II score[25], and combinations of 1) and 2). To assess whether incorporating plasma albumin to the multivariable model provided incremental prognostic value, the likelihood ratio test for nested models was used. Discrimination was also assessed by integrated discrimination index (IDI) and clinical risk stratification by net reclassification improvement (NRI) [26]. Results from the regression analyses are presented as odds ratios (ORs) with 95% confidence intervals (CIs). A two-sided p -value < 0.05 was regarded statistically significant. Data were analyzed using the SPSS statistical package, version 23 (IBM Corp, Armonk, NY) with the exception of the reclassification analyses which were performed with R version 3.5.1[27] using packages Hmisc and pROC.

Results

Patient characteristics

The mean age in the cohort was 66 years, and 26% were women. On average, mean arterial pressure at inclusion was 57 (SD 11) mmHg. The most common etiology of cardiogenic shock was acute coronary syndrome (ACS) (80%). The overall 90-day all-cause mortality was 42%. The mean baseline P-Alb was 29.5 g/L (SD 6.4 g/L, range 11–42 g/L). Hypoalbuminemia (P-Alb < 34 g/l) at admission was observed in 75% (134/178) of patients. There was no difference in the P-Alb levels at baseline between ACS and non-ACS etiologies of cardiogenic shock (P-Alb 29.8 g/L vs. 28.3 g/L, $p = 0.7$)

Characteristics of hypoalbuminemic cardiogenic shock patients

Baseline characteristics and clinical presentation of patients with and without hypoalbuminemia are shown in [Table 1](#). Compared to patients with normal P-Alb levels, hypoalbuminemic patients were more likely to have a history of chronic diseases, such as prior myocardial infarction, ischemic heart disease, heart failure, and worse renal function. There were fewer current smokers and less use of calcium channel blockers in the hypoalbuminemic group. Notably, BMI was lower in the hypoalbuminemic group compared to the group with normal albumin levels.

As shown in [Table 2](#), there were no differences in lactate, mean arterial pressure, or systolic blood pressure between the groups. However, patients with hypoalbuminemia were more likely to have pulmonary oedema on chest X-ray, as well as higher levels of NT-proBNP and

Table 1. Patient characteristics and mortality in normoalbuminemic and hypoalbuminemic cardiogenic shock patients.

	All	Normoalbuminemia (P-Alb ≥34g/L)	Hypoalbuminemia (P-Alb <34 g/L)	p-value
Demographics	(n = 178)	(n = 44)	(n = 134)	
Age, years; mean (SD)	66 (12)	64 (12)	67 (12)	0.10
Smoking	72 (41)	23 (54)	49 (37)	0.05
Women	46 (26)	33 (29)	13 (20)	0.20
BMI, kg/m ² ; mean (SD)	27.0 (4)	28.2 (4)	26.6 (4)	0.03
Medical history				
Hypertension	108 (61)	29 (66)	79 (59)	0.41
Coronary artery disease	58 (33)	9 (21)	49 (37)	0.05
Previous myocardial infarction	45 (25)	5 (11)	40 (30)	0.01
Prior CABG	11 (6)	1 (2)	10 (8)	0.30
History of HFrEF	22 (13)	1 (2)	21 (16)	0.02
Diabetes mellitus	53 (30)	9 (21)	44 (33)	0.12
Medications in use at admission				
ACEI	53 (30)	15 (34)	37 (28)	0.51
ARB	26 (15)	6 (14)	20 (15)	0.81
Calcium-channel blockers	22 (12)	10 (23)	13 (10)	0.04
Beta-blocker	67 (38)	14 (32)	53 (40)	0.42
Diuretics	53 (31)	11 (26)	42 (32)	0.45
Clinical presentation				
Cold periphery	170 (96)	40 (93)	130 (97)	0.24
Confusion	117 (67)	29 (66)	88 (67)	0.93
Oliguria	94 (54)	24 (55)	70 (53)	0.90
Lactate > 2	125 (71)	29 (66)	96 (73)	0.35
ACS etiology	143 (80)	38 (86)	105 (78)	0.25
Lung oedema on X-ray	60 (36)	10 (23)	50 (40)	0.04
Systolic BP, mmHg; mean (SD)	77 (12)	76 (12)	79 (13)	0.52
Mean arterial pressure, mmHg; mean (SD)	57 (11)	58 (12)	57 (10)	0.43
Heart rate, beats/min; mean (SD)	88 (29)	87 (30)	89 (29)	0.77
LVEF, %; mean (SD)	33 (14)	35 (13)	32 (14)	0.09
Time from detection of shock to baseline, h:min; median (IQR)	2:00 (0:22–4:00)	2:00 (0:00–4:03)	2:00 (0:30–3:30)	0.86
Mortality				
90-day mortality	74 (42)	10 (23)	64 (48)	0.004

Results shown as n (%) for categorical and mean (SD) or median (IQR) for continuous variables. ACEI = angiotensin-converting enzyme inhibitor; ACS = acute coronary syndrome; ALT = alanine aminotransferase; ARB = angiotensin receptor blocker; BMI = body mass index; BP = blood pressure; CABG = coronary artery bypass grafting; HFrEF = heart failure with reduced ejection fraction; IQR = interquartile range; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal prohormone of B-type natriuretic peptide; SD = standard deviation

<https://doi.org/10.1371/journal.pone.0217006.t001>

CRP, and lower levels of haemoglobin at baseline. There were no significant differences in liver function tests (alanine aminotransferase, alkaline phosphatase and total bilirubin) at baseline. In multivariable analysis, independent associates of hypoalbuminemia were higher CRP at baseline, pulmonary oedema on chest X-ray, history of heart failure with reduced ejection fraction, older age and calcium channel blocker use prior to admission (Table 3). Coronary angiography was performed in 136 patients, in which patients with hypoalbuminemia were more likely to have multi-vessel disease. Post-PCI, a higher proportion of patients with hypoalbuminemia had a TIMI grade flow of less than 3, but the difference was not statistically significant.

Table 2. Laboratory test results and angiographic findings in normoalbuminemic and hypoalbuminemic cardiogenic shock patients.

	All	Normoalbuminemia (P-Alb ≥34g/L)	Hypoalbuminemia (P-Alb <34 g/L)	p-value
Laboratory test results at baseline	(n = 178)	(n = 44)	(n = 134)	
eGFR, ml/min/1.73m ² ; mean (SD)	63 (30)	69 (26)	60 (30)	0.04
NT-proBNP, ng/L; median (IQR)	2710 (585–9434)	866 (226–5029)	3769 (1037–11745)	<0.001
CRP, mg/L; median (IQR)	16 (4–54)	7 (2–19)	25 (5–75)	<0.001
Leukocytes, 10E ⁹ ; mean (SD)	14.0 (5.4)	14.7 (6.0)	13.8 (5.3)	0.30
Hemoglobin, g/L; mean (SD)	129 (23)	139 (20)	125 (23)	<0.001
Albumin (g/L), mean (SD)	29.5 (6.4)	37.2 (2.3)	27.0 (5.1)	
Lactate (mmol/L); median (IQR)	2.7 (1.7–5.8)	2.4 (1.5–5.1)	2.9 (1.7–5.9)	0.15
hsTnT (ng/L); median (IQR)	2260 (398–5418)	2601 (386–6940)	2108 (403–5362)	0.69
Alanine aminotransferase (IU/L); median (IQR)	44 (20–92)	42 (22–86)	45 (20–103)	0.90
Alkaline phosphatase (IU/L); median (IQR)	61 (49–81)	67 (53–91)	60 (47–78)	0.11
Total bilirubin (umol/L); median (IQR)	9.6 (5.7–15.4)	10.0 (5.6–16.1)	9.5 (5.7–15.2)	0.95
Change in albumin between baseline and 72h (ΔAlb 0-72h) (g/L); mean (SD)	-5.0 (6.4)	-10.2 (6.2)	-2.5(4.7)	<0.001
Fluid balance at 72h (ml); mean (SD)	1389 (4241)	1765 (4215)	692 (4116)	0.19
Angiographic findings	(n = 136)	(n = 36)	(n = 100)	
Multivessel disease; n (%)	93 (68)	18 (50)	75 (75)	0.006
TIMI flow <3 post PCI	37 (30)	6 (18)	31 (35)	0.06
PCI complications	44 (28)	12 (29)	32 (27)	0.77

Results shown as n (%) for categorical and mean (SD) or median (IQR) for continuous variables. CRP = C-reactive protein; eGFR = estimated glomerular filtration rate; IQR = interquartile range; NT-proBNP = N-terminal prohormone of B-type natriuretic peptide; PCI = percutaneous coronary intervention; SD = standard deviation; TIMI = thrombolysis in myocardial infarction

<https://doi.org/10.1371/journal.pone.0217006.t002>

Hypoalbuminemia and outcome

Hypoalbuminemia at baseline was associated with a higher 90-day mortality compared to normal P-Alb levels (48% vs 23%, p = 0.004; Fig 1). Fig 2 shows that 90-day mortality increased across P-Alb quartiles from 23% in the highest quartile to 57% in the lowest quartile (p<0.001 for trend).


In unadjusted logistic regression analysis, baseline P-Alb had an OR of 2.4 per 10 g/L decrement (95% CI 1.5–4.1, p = 0.001). Multivariable adjustment did not significantly alter the results. Lower baseline albumin was associated with mortality independently of the CardShock risk score, the IABP-SHOCK II score and the variables associated with hypoalbuminemia (Table 4). Addition of P-Alb improved the risk prediction model compared with either the

Table 3. Factors independently associated with hypoalbuminemia at baseline.

	Odds ratio	95% CI	p-value
CRP at baseline; mg/L	1.02	1.003–1.03	0.01
Lung oedema on chest X-ray	2.9	1.2–7.1	0.02
History of HFrEF	11.7	1.4–98	0.02
Age; years	1.04	1.01–1.07	0.02
Use of calcium-channel blocking medication	0.3	0.1–0.9	0.03

CI = confidence interval; HFrEF = heart failure with reduced ejection fraction

<https://doi.org/10.1371/journal.pone.0217006.t003>



No. at risk					
≥34 g/L	43	36	35	33	
<34 g/L	133	74	72	69	

Fig 1. Kaplan-Meier survival curves of 90-day mortality according to baseline plasma albumin (P-Alb).

<https://doi.org/10.1371/journal.pone.0217006.g001>

CardShock risk score or the IABP-SHOCK II score alone ($\chi^2 = 5.301$, $p = 0.02$ and $\chi^2 = 7.088$, $p = 0.008$ for comparison of nested models, respectively). Discrimination was also assessed using integrated discrimination index (IDI) and clinical risk stratification by net reclassification improvement (NRI) (Table 5).

Serial P-Alb measurements and changes during hospitalization

Plasma albumin concentrations decreased during hospitalization, on average -5.0 g/L during the first 72 hours ($\Delta\text{Alb}_{0-72\text{h}}$). Albumin levels decreased similarly in survivors and non-survivors (-4.6 g/L vs. 5.4 g/L, $p = 0.5$, Fig 3A). The P-Alb levels were lower for non-survivors throughout the follow-up period of 72 hours compared to 90-day survivors. The downward trend in P-Alb from baseline until 72h was statistically significant for both survivors and non-survivors ($p < 0.001$ for both). P-Alb decreased more rapidly among patients with normal P-Alb at baseline compared with hypoalbuminemic patients (Table 2, Fig 3B). However, P-Alb decrease ($\Delta\text{Alb}_{0-72\text{h}}$) was not associated with mortality, even after adjustment for baseline P-Alb (OR 1.0, 95% CI 0.94–1.06, $p = 0.87$, adjusted for baseline albumin OR 0.94, 95% CI




Fig 2. 90-day mortality by baseline albumin quartiles. The P-Alb ranges for the quartiles were 34.0–42.9 g/L for the 1st quartile, 30.0–33.9 g/L for the 2nd quartile, 25.9–29.9 g/L for the 3rd quartile and 10.4–25.9 g/L for the 4th quartile.

<https://doi.org/10.1371/journal.pone.0217006.g002>

0.87–1.02, $p = 0.17$). At 72 h, Δ Alb0-72h correlated negatively with fluid balance (Pearson correlation coefficient (r_p) = -0.41, $p < 0.001$) and with CRP (Spearman correlation coefficient (r_s) = -0.41, $p < 0.001$), but positively with alkaline phosphatase ($r_s = 0.28$, $p = 0.002$) and total bilirubin ($r_s = 0.26$, $p = 0.005$). The negative correlation with central venous pressure at 72h had borderline significance ($r_p = -0.26$, $p = 0.051$).

Discussion

This is the first study on the prevalence and prognostic value of P-Alb in cardiogenic shock. First, low P-Alb was a frequent finding (75%) early in cardiogenic shock, with most of the

Table 4. Unadjusted and adjusted odds ratios for baseline plasma albumin with 90-day mortality.

	Baseline plasma albumin per 10 g/L decrease	95% CI	p-value
Unadjusted	OR 2.4	1.5–4.1	0.001
Adjusted with variables associated with hypoalbuminemia ^a	OR 2.9	1.2–7.1	0.02
Adjusted with CSS score ^b	OR 2.0	1.1–3.8	0.03
Adjusted with CSS score ^b and variables associated with hypoalbuminemia ^a	OR 2.9	1.02–8.4	0.045
Adjusted with IABP-SHOCK II score ^c	OR 2.5	1.2–5.0	0.01
Adjusted with IABP-SHOCK II score ^c and variables associated with hypoalbuminemia ^a	OR 7.4	1.7–31.3	0.007

OR = odds ratio; CI = confidence interval

^aComorbidities (heart failure with reduced ejection fraction, ischaemic heart disease), smoking status, calcium-channel blocker use, lung oedema on X-ray, body mass index, haemoglobin, NT-proBNP and CRP at baseline, presence of multi-vessel disease in primary coronary angiography

^bage >75 years (1 point), history of myocardial infarction or coronary bypass (1 point), altered mental status at presentation (1 point), ACS etiology (1 point), left ventricular ejection fraction <40% (1 point), lactate (2–4 mmol/l = 1 point, >4 mmol/l = 2 points) and estimated glomerular filtration rate on admission (60–30 mL/min/1.73 m² = 1 point, <30 mL/min/1.73 m² = 2 points)

^cAge >73 years (1 point), history of stroke (1 point), blood glucose >10.6 g/L at baseline (1 point), creatinine >132.6 umol/L at baseline (1 point), TIMI flow <3 post-PCI (2 points), blood lactate >5 mmol/L (2 points)

<https://doi.org/10.1371/journal.pone.0217006.t004>

Table 5. Comparison of cardiogenic shock risk score models.

Model	AUC (95% CI)	Continuous NRI (95% CI)	IDI (95% CI)
CardShock risk score	0.798 (0.734–0.862)		
CardShock risk score + P-Alb	0.819 (0.757–0.881)	0.297 (-0.006–0.600)	0.027 (0.003–0.051)
IABP II SHOCK -score	0.719 (0.629–0.808)		
IABP II SHOCK -score + P-Alb	0.750 (0.661–0.839)	0.355 (-0.004–0.715)	0.054 (0.013–0.095)

AUC = area under curve; CI = confidence interval; IDI = integrated discrimination index; NRI = net reclassification index; P-Alb = baseline plasma albumin

<https://doi.org/10.1371/journal.pone.0217006.t005>

patients having values below 30 g/L already at baseline. Second, hypoalbuminemia was associated with higher mortality independent of other variables. Third, P-Alb levels decreased during hospitalization in all patients, but the rate of change was not associated with 90-day




Fig 3. A: Mean plasma albumin at different time points during hospitalization in 90-day survivors and non-survivors of cardiogenic shock. Mean change between 0 and 72h -4.6 g/L for survivors, -5.4 g/L for non-survivors; $p = 0.54$. **B: Plasma albumin at different time points during hospitalization in patients with normoalbuminemia or hypoalbuminemia at baseline.** Mean change between 0 and 72 h -10.8 mg/L for normoalbuminemic patients and -2.5 mg/L for hypoalbuminemic patients; $p < 0.001$. P-values in the picture represent results for linear mixed model analysis of variance for repeated measures. * $p < 0.05$ § $p < 0.10$ for the difference in P-Alb between groups at this time point (Student's t-test). Error bar = standard deviation.

<https://doi.org/10.1371/journal.pone.0217006.g003>

mortality. Nevertheless, plasma albumin levels were lower in non-survivors compared to survivors during the duration of the study period.

The high proportion of hypoalbuminemic patients in this study was striking, and probably has various causes. First, the association of hypoalbuminemia with comorbidities suggests that hypoalbuminemia may be a pre-existing condition, perhaps linked with frailty and nutritional status, as the lower hemoglobin levels and BMI in the hypoalbuminemic group could suggest. Second, it has been suggested that hypoalbuminemia might predispose STEMI patients to cardiogenic shock[16], which would lead to a higher prevalence of hypoalbuminemia in cardiogenic shock populations (75% in our study compared to 30% in STEMI[16]). Furthermore, inflammatory response and SIRS in cardiogenic shock[28] increase capillary permeability promoting the transcapillary escape rate of albumin[6]. Interestingly, hypoalbuminemia did not appear to be linked to the severity of cardiogenic shock, as for example lactate or blood pressure levels did not differ between normo- and hypoalbuminemic patients.

Hypoalbuminemia has been shown to be associated with worse outcomes in acute coronary syndromes[15,16], acute heart failure[17,18] and critical illness[7,29,30]. We show that in cardiogenic shock mortality increases in a linear fashion with decreasing baseline P-Alb levels. Patients with normal albumin levels at baseline had a relatively favourable outcome, whereas moderate or severe hypoalbuminemia was associated with two-fold higher mortality. In a meta-analysis of hypoalbuminemia in acutely ill patients, it was estimated that each 10 g/L decrease in serum albumin concentration increased the odds of mortality by 137%[2]. In line with this estimation the unadjusted odds of 90-day mortality increased by 140% for each 10g/l decrement in our study, and lower albumin levels were significantly associated with mortality in analyses adjusted for multiple covariates.

The independent association of hypoalbuminemia with mortality suggests that hypoalbuminemia may have effects on mortality which are not explained by other variables interacting with hypoalbuminemia. Oduncu et al. suggested that hypoalbuminemia may play a direct role in poor reperfusion after PCI[16]. Interestingly in this respect, albumin has been suggested to have anticoagulative properties[29]. It has also been implied that albumin may be associated with disease severity instead of just the presence or absence of disease, in which case categorizing pre-existing diseases as binary variables may lead to attributing the risk caused by disease severity to albumin[1]. In our study, there was a trend for TIMI flow <3 after primary PCI in hypoalbuminemic patients, however, the presence of multi-vessel coronary artery disease did not interfere with the independent association of P-Alb with mortality.

There are several possible pathways to explain the association between hypoalbuminemia, cardiogenic shock, outcome and the laboratory parameters associated with hypoalbuminemia in this study, such as lower hemoglobin and higher CRP-values, which may act in concert. One possible explanation could be aggressive fluid resuscitation prior to study enrollment and congestion leading to worse outcomes. Unfortunately, we do not have available data on fluid resuscitation prior to study enrollment to assess this possibility, but after study enrollment the fluid balance between normo- and hypoalbuminemic patients did not differ. Another possible pathway could be pre-existing chronic illness resulting in low-grade inflammation raising CRP, which would lead to anemia of chronic illness and hypoalbuminemia[31]. Also, infection or higher levels of inflammation reflected by the higher CRP-levels in hypoalbuminemic patients could lead to capillary leakage of albumin resulting in hypoalbuminemia[6].

In this study, there was no association between the rate of decrease in P-Alb during the first 72 hours and 90-day mortality. The significance of changes in albumin has been explored in ICU patients, but data are conflicting [7, 28]. We found that the rate of decrease of P-Alb was associated with the baseline level and differed between normo- and hypoalbuminemic patients. Correlations between Δ Alb0-72h and CRP, Bilirubin and AFOS at 72 hours also suggest that

inflammation and cholestatic liver injury may play a role in the rate of decrease of P-Alb in cardiogenic shock.

The high prevalence of hypoalbuminemia and its independent association with outcome suggests that measuring P-Alb levels early in cardiogenic shock should be incorporated in clinical practice. As can be seen in Fig 3A, low P-Alb at later time points was also associated with mortality, but the association was strongest for early albumin levels (0-12h). As discussed above, albumin levels are subject to change due to various reasons and the rate of change did not predict mortality. As intravenous use of albumin has been shown not to decrease mortality in the critically ill [32], further studies are needed to determine if there are any other therapeutic options that would specifically target the worse prognosis associated with hypoalbuminemia in cardiogenic shock.

Our study has some limitations. First, it was not possible to have data on the patients' albumin levels before study enrollment to determine whether the observed hypoalbuminemia was pre-existing or not. Second, we did not have information on the fluid status prior to study enrollment, as haemodilution due to excessive fluid resuscitation could be one of the causes of hypoalbuminemia. Third, although adjustments were made for various variables found to associate with hypoalbuminemia, there may be confounding factors we were unable to account for, leading to an overestimation of the independent association of P-Alb with mortality. However, the estimated ORs are in accordance with previous studies on the effect of hypoalbuminemia on mortality and the results were consistent in multiple analyses.

Conclusions

In conclusion, hypoalbuminemia was a very frequent finding in the early phase of cardiogenic shock. P-Alb at baseline was independently associated with 90-day all-cause mortality, with mortality increasing across lower albumin quartiles. This study found that P-Alb is a prognostic marker in cardiogenic shock, and we suggest incorporating P-Alb measurement as part of the assessment of patients with cardiogenic shock.

Supporting information

S1 Table. Causes of death as reported by local investigators.
(DOCX)

S1 Dataset. De-identified patient data used in the study.
(XLSX)

Acknowledgments

The CardShock study investigators in all participating hospitals. The CardShock steering committee: Veli-Pekka Harjola (chair), Marek Banaszewski, Lars Køber, Johan Lassus, Alexandre Mebazaa, Marco Metra, John Parissis, Jose Silva-Cardoso, Alessandro Sionis, Salvatore Di Somma, and Jindrich Spinar. List of investigators: Athens: Katerina Koniari, Astrinos Voumvourakis, Apostolos Karavidas; Barcelona: Jordi Sans-Rosello, Montserrat Vila, Albert Duran-Cambra; Brescia: Marco Metra, Michela Bulgari, Valentina Lazzarini; Brno: Jiri Parenica, Roman Stipal, Ondrej Ludka, Marie Palsuva, Eva Ganovska, Petr Kubena; Copenhagen: Matias G. Lindholm, Christian Hassager; Helsinki: Tom Bäcklund, Raija Jurkko, Kristiina Järvinen, Tuomo Nieminen, Kari Pulkki, Leena Soinen, Reijo Sund, Ilkka Tierala, Jukka Tolonen, Marjut Varpula, Tuomas Korva, Anne Pitkälä; Rome: Rossella Marino; Porto: Alexandra Sousa, Carla Sousa, Mariana Paiva, Inês Rangel, Rui Almeida, Teresa Pinho, Maria Júlia

Maciel; Warsaw: Janina Stepinska, Anna Skrobisz, Piotr Góral. The study was performed in collaboration with the GREAT network.

Author Contributions

Conceptualization: Toni Jääntti, Alexandre Mebazaa, Johan Lassus.

Data curation: Toni Jääntti, Tuukka Tarvasmäki, Kari Pulkki, Tuija Javanainen, Heli Tolppanen, Raija Jurkko, Mari Hongisto, Anu Kataja, Alessandro Sionis, Jose Silva-Cardoso, Marek Banaszewski, Jindrich Spinar, Johan Lassus.

Formal analysis: Toni Jääntti.

Funding acquisition: Veli-Pekka Harjola.

Investigation: Toni Jääntti, Tuukka Tarvasmäki, John Parissis, Kari Pulkki, Tuija Javanainen, Heli Tolppanen, Raija Jurkko, Mari Hongisto, Anu Kataja, Alessandro Sionis, Jose Silva-Cardoso, Marek Banaszewski, Jindrich Spinar, Johan Lassus.

Methodology: Toni Jääntti, Tuukka Tarvasmäki, Kari Pulkki, Alexandre Mebazaa, Johan Lassus.

Project administration: Veli-Pekka Harjola, John Parissis, Raija Jurkko, Alessandro Sionis, Jose Silva-Cardoso, Marek Banaszewski, Jindrich Spinar, Johan Lassus.

Resources: Veli-Pekka Harjola, John Parissis, Kari Pulkki, Alessandro Sionis, Jose Silva-Cardoso, Marek Banaszewski, Jindrich Spinar, Johan Lassus.

Supervision: Veli-Pekka Harjola, Alexandre Mebazaa, Johan Lassus.

Visualization: Toni Jääntti.

Writing – original draft: Toni Jääntti.

Writing – review & editing: Toni Jääntti, Tuukka Tarvasmäki, Veli-Pekka Harjola, John Parissis, Kari Pulkki, Tuija Javanainen, Heli Tolppanen, Raija Jurkko, Mari Hongisto, Anu Kataja, Alessandro Sionis, Jose Silva-Cardoso, Marek Banaszewski, Jindrich Spinar, Alexandre Mebazaa, Johan Lassus.

References

1. Goldwasser P, Feldman J. Association of serum albumin and mortality risk. *Journal of Clinical Epidemiology*. 1997; 50: 693–703. PMID: [9250267](#)
2. Vincent J-L, Dubois M-J, Navickis RJ, Wilkes MM. Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials. *Ann Surg*. 2003; 237: 319–334. <https://doi.org/10.1097/01.SLA.0000055547.93484.87> PMID: [12616115](#)
3. Gibbs J, Cull W, Henderson W, Daley J, Hur K, Khuri SF. Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study. *Arch Surg*. 1999; 134: 36–42. PMID: [9927128](#)
4. Friedman AN, Fadem SZ. Reassessment of albumin as a nutritional marker in kidney disease. *J Am Soc Nephrol. American Society of Nephrology*; 2010; 21: 223–230. <https://doi.org/10.1681/ASN.2009020213> PMID: [20075063](#)
5. Levitt DG, Levitt MD. Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. *Int J Gen Med*. 2016; 9: 229–255. <https://doi.org/10.2147/IJGM.S102819> PMID: [27486341](#)
6. Fleck A, Raines G, Hawker F, Trotter J, Wallace PI, Ledingham IM, et al. Increased vascular permeability: a major cause of hypoalbuminaemia in disease and injury. *The Lancet*. 1985; 1: 781–784.
7. McCluskey A, Thomas AN, Bowles BJ, Kishen R. The prognostic value of serial measurements of serum albumin concentration in patients admitted to an intensive care unit. *Anaesthesia*. 1996; 51: 724–727. PMID: [8795312](#)

8. Davidson J, Goodman D, Waldmann TA, Gordon R JR. PROTEIN-LOSING GASTROENTEROPATHY IN CONGESTIVE HEART-FAILURE. *The Lancet*. 1961; 277: 899–902. [https://doi.org/10.1016/S0140-6736\(61\)91768-8](https://doi.org/10.1016/S0140-6736(61)91768-8)
9. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. *Am J Kidney Dis*. 1990; 15: 458–482. PMID: [2333868](https://pubmed.ncbi.nlm.nih.gov/2333868/)
10. Sung J, Bochicchio GV, Joshi M, Bochicchio K, Costas A, Tracy K, et al. Admission serum albumin is predictive of outcome in critically ill trauma patients. *Am Surg*. 2004; 70: 1099–1102. PMID: [15663053](https://pubmed.ncbi.nlm.nih.gov/15663053/)
11. Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. *Cancer*. 1993; 72: 3091–3098. PMID: [8221576](https://pubmed.ncbi.nlm.nih.gov/8221576/)
12. Horwich TB, Kalantar-Zadeh K, MacLellan RW, Fonarow GC. Albumin levels predict survival in patients with systolic heart failure. *American Heart Journal*. 2008; 155: 883–889. <https://doi.org/10.1016/j.ahj.2007.11.043> PMID: [18440336](https://pubmed.ncbi.nlm.nih.gov/18440336/)
13. Liu M, Chan C-P, Yan BP, Zhang Q, Lam Y-Y, Li R-J, et al. Albumin levels predict survival in patients with heart failure and preserved ejection fraction. *European Journal of Heart Failure*. 2014; 14: 39–44. <https://doi.org/10.1093/eurjhf/hfr154> PMID: [22158777](https://pubmed.ncbi.nlm.nih.gov/22158777/)
14. Corti MC. Serum albumin level and physical disability as predictors of mortality in older persons. *JAMA: The Journal of the American Medical Association*. 1994; 272: 1036–1042. <https://doi.org/10.1001/jama.272.13.1036> PMID: [8089886](https://pubmed.ncbi.nlm.nih.gov/8089886/)
15. Hartopo AB, Gharini PPR, Setianto BY. Low Serum Albumin Levels and In-Hospital Adverse Outcomes in Acute Coronary Syndrome. *International Heart Journal*. International Heart Journal Association; 2010; 51: 221–226. <https://doi.org/10.1536/ihj.51.221>
16. Oduncu V, Erkol A, Karabay CY, Kurt M, Akgün T, Bulut M, et al. The prognostic value of serum albumin levels on admission in patients with acute ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention. *Coronary Artery Disease*. 2013; 24: 88–94. <https://doi.org/10.1097/MCA.0b013e32835c46fd> PMID: [23249632](https://pubmed.ncbi.nlm.nih.gov/23249632/)
17. Ambrosy AP, Vaduganathan M, Huffman MD, Khan S, Kwasny MJ, Fought AJ, et al. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. *European Journal of Heart Failure*. 2014; 14: 302–311. <https://doi.org/10.1093/eurjhf/hfs007> PMID: [22357577](https://pubmed.ncbi.nlm.nih.gov/22357577/)
18. Bonilla-Palomas JL, Gámez-López AL, Moreno-Conde M, López-Ibáñez MC, Anguita-Sánchez M, Gallego de la Sacristana A, et al. Hypoalbuminemia in acute heart failure patients: causes and its impact on hospital and long-term mortality. *Journal of Cardiac Failure*. Elsevier; 2014; 20: 350–358. <https://doi.org/10.1016/j.cardfail.2014.01.016> PMID: [24486927](https://pubmed.ncbi.nlm.nih.gov/24486927/)
19. Uthamalingam S, Kandala J, Daley M, Patvardhan E, Capodilupo R, Moore SA, et al. Serum albumin and mortality in acutely decompensated heart failure. *American Heart Journal*. Elsevier; 2010; 160: 1149–1155. <https://doi.org/10.1016/j.ahj.2010.09.004> PMID: [21146671](https://pubmed.ncbi.nlm.nih.gov/21146671/)
20. van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, et al. Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association. *Circulation*. 2017; 136: e232–e268. <https://doi.org/10.1161/CIR.0000000000000525> PMID: [28923988](https://pubmed.ncbi.nlm.nih.gov/28923988/)
21. Harjola V-P, Lassus J, Sionis A, Køber L, Tarvasmäki T, Spinar J, et al. Clinical picture and risk prediction of short-term mortality in cardiogenic shock. *European Journal of Heart Failure*. 2015; 17: 501–509. <https://doi.org/10.1002/ejhf.260> PMID: [25820680](https://pubmed.ncbi.nlm.nih.gov/25820680/)
22. Reyentovich A, Barghash MH, Hochman JS. Management of refractory cardiogenic shock. *Nature Publishing Group*. Nature Publishing Group; 2016; 13: 481–492. <https://doi.org/10.1038/nrcardio.2016.96> PMID: [27356877](https://pubmed.ncbi.nlm.nih.gov/27356877/)
23. Arques S, Roux E, Stolidi P, Gelisse R, Ambrosi P. Usefulness of serum albumin and serum total cholesterol in the prediction of hospital death in older patients with severe, acute heart failure. *Arch Cardiovasc Dis*. 2011; 104: 502–508. <https://doi.org/10.1016/j.acvd.2011.06.003> PMID: [22044702](https://pubmed.ncbi.nlm.nih.gov/22044702/)
24. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med*. NIH Public Access; 2009; 150: 604–612. PMID: [19414839](https://pubmed.ncbi.nlm.nih.gov/19414839/)
25. Pöss J, Köster J, Fuernau G, Eitel I, de Waha S, Ouarrak T, et al. Risk Stratification for Patients in Cardiogenic Shock After Acute Myocardial Infarction. *J Am Coll Cardiol*. 2017; 69: 1913–1920. <https://doi.org/10.1016/j.jacc.2017.02.027> PMID: [28408020](https://pubmed.ncbi.nlm.nih.gov/28408020/)
26. Pencina MJ, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. *Stat Med*. John Wiley & Sons, Ltd; 2008; 27: 157–72– discussion 207–12. <https://doi.org/10.1002/sim.2929> PMID: [17569110](https://pubmed.ncbi.nlm.nih.gov/17569110/)

27. R Core Team. R: A Language and Environment for Statistical Computing. Available: <http://www.R-project.org/>
28. Kohsaka S, Menon V, Lowe AM, Lange M, Dzavik V, Sleeper LA, et al. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. *Arch Intern Med. American Medical Association*; 2005; 165: 1643–1650. <https://doi.org/10.1001/archinte.165.14.1643> PMID: [16043684](https://pubmed.ncbi.nlm.nih.gov/16043684/)
29. Knaus WA, Wagner DP, Draper EA, Zimmerman JE, Bergner M, Bastos PG, et al. The APACHE III Prognostic System. *Chest*. 1991; 100: 1619–1636. <https://doi.org/10.1378/chest.100.6.1619> PMID: [1959406](https://pubmed.ncbi.nlm.nih.gov/1959406/)
30. Yap FHY, Joynt GM, Buckley TA, Wong ELY. Association of serum albumin concentration and mortality risk in critically ill patients. *Anaesth Intensive Care*. 2002; 30: 202–207. <https://doi.org/10.1177/0310057X0203000213> PMID: [12002929](https://pubmed.ncbi.nlm.nih.gov/12002929/)
31. Kaysen GA. Biochemistry and biomarkers of inflamed patients: why look, what to assess. *Clin J Am Soc Nephrol*. 2009; 4 Suppl 1: S56–63. <https://doi.org/10.2215/CJN.03090509> PMID: [19996007](https://pubmed.ncbi.nlm.nih.gov/19996007/)
32. Patel A, Laffan MA, Waheed U, Brett SJ. Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality. *BMJ. British Medical Journal Publishing Group*; 2014; 349: g4561–g4561. <https://doi.org/10.1136/bmj.g4561> PMID: [25099709](https://pubmed.ncbi.nlm.nih.gov/25099709/)